

CURRICULUM VITAE

รองศาสตราจารย์ ดร. เกียรติกร ชลภัทร สุขเกษม

Associate Professor B. Pharm, Ph.D. Chonlaphat Sukasem

E-mail address chonlaphat.suk@mahidol.ac.th, chonlaphat_suk@hotmail.com.

Contact address Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine, Ramathibodi Hospital; Rama 6 Road, Bangkok 10400, Thailand

Telephone: (662)-200-4330-2, Fax: (66)-02-200-4332



Current status

1. Head, Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University
2. Chief, Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center, Ramathibodi Hospital
3. Project Director, Pharmacogenomics for Autistic Child, Khon Poom Foundation, The Project in Her Royal Highness Princess Ubonratana Rajakanya Siritwatana Bhanawadee
4. Secretariat, Doctor of Philosophy (Clinical Pathology), Faculty of Graduate, Mahidol University
5. Chair, Institutional Biosafety and Chemical Safety Committee, Faculty of Medicine Ramathibodi Hospital, Mahidol University.
6. Member, Committee for Biological and Animal Toxin Act, Ministry of Public Health.

Scientific Association member

1. Secretariat, Biosafety Association Thailand
2. Executive committee, Virology Association Thailand

Education

-Post-Doctoral researcher, Laboratory for Cardiovascular Diseases/ Laboratory for International Alliance, Research Group for Pharmacogenomics, RIKEN Center for Genomics Medicine , Yokohama, Japan; 2009

“Pharmacogenomics study aspirin responsiveness in cardiovascular and type 2 diabetes diseases; Genome wide and candidate gene approaches”

-Post-Doctoral training, Inserm ER 19, Laboratoire de Virologie, Virus, pseudovirus: morphogenese et antigenecite, Faculty of Medicine, Universite’ Francois-Rabelais, Tours, France, 2007-2008

“Identify the molecular characteristics of the env gene and determination of HIV tropism using pseudotyped viruses”

-Ph. D. (Pathobiology) Faculty of Science, Mahidol University, Thailand, 2006-2007

“Molecular characterization of drug resistance and subtype diversity in HIV-1 infected patients: Implication for subtype-specific mutational pathway on protease and reverse transcriptase genotype”

-B. in Pharm, Faculty of Pharmacy, Rangsit University, Thailand, 2001

Training

- Certification of “Genome Wide Association Analysis 2008” Center of Pharmacogenomics and Bioinformatics, Thailand, 2008

- Certificate of competency on “Biosafety Management course programme” Asia-Pacific Biosafety Association (A-PBA), Singapore, 2008

- Certificate of competency on “Engineering for Biosafety” Asia-Pacific Biosafety Association (A-PBA) (Accredited by WHO), Singapore, 2008

- Certificate of competency on “Aerobiology; Principle and Application”, Asia-Pacific Biosafety Association, Thailand, 2008

- Certificate of competency on “BSL3 Laboratory; Essentials of Facility Design and Construction Techniques”, Asia-Pacific Biosafety Association, Thailand, 2008

- Certificate of competency on “BSL-3 Training the trainer” by Emory University and CDC/NIH, Thailand, 2008

- GLP, Ramathibodi Hospital

- GCP, Ramathibodi Hospital
- GCP, Ministry of Public Health
- Microarray and Bioinformatics, CapitalBio, Beijing, China, 2007
- HIV treatment, prevention and pathogenesis, Sydney, Australia, 2007
- Certificate of competency on “Dangerous goods awareness with concentration on proceeding, handling and transporting infectious substances by air course”, World Courier, Thailand, 2006
- Management of DNA banking: anonymization of specimens, U.S.A., 2005
- Drug discovery and development, Singapore, 2005
- Biotechnology and Industry Organization (BIO) 2005, U.S.A.
- Bioentrepreneur workshop, Thailand, 2004.
- Experimental design methodology and analysis for animal model, Thailand, 2002
- Safe animal practice in research and biochemical drug manufacturing, Thailand, 2002

Scholarships and Awards

- Award for Outstanding research, the research entitled “Study of hepatotoxicity of *Cassia Siamea Lamk* in Rat”
- Franco-Thai Cooperation Program in Higher Education and Research, 2007 for Post-Doctoral training, Inserm ER 19, Laboratoire de Virologie, Virus, pseudovirus: morphogenese et antigenecite, Faculty of Medicine, Universite’ Francois-Rabelais, Tours, France
- Franco-Thai Cooperation Program in Higher Education and Research, 2008 for Research training and collaboration development at
 - (1) Service de Bacteriologie-Virologie, Saint-Louis Hospital, Paris, France
(Prof. Francois Simon)
 - (2) Unite de Virologie Generale, Departement de Microbiologie, CHU de Rouen, Rouen, France
(Dr, Jean-Christophe Plantier)
 - (3) Departement de Bacteriologie-Virologie et Hygiene Hospitaliere, Hospital Pontchailou, France
(Dr. Annick Ruffault)

- Post-Doctoral fellow scholarship, RIKEN Center for Genomics Medicine, Yokohama, Japan; 2009
- U.S. Department of State's Bio Engagement Program (BEP), Biotechnology Industry Organization (BIO) 2010, USA. 2010
- European Erasmus Mundus, Maheva action 2, 2012 for Analysis of repertoire, Ig and TCR in mouse and human models-Application for biomarkers discovery, Immunology- Immunopathology, Immunotherapy Laboratory (I3), Faculty of Medicine, University Pierre et Marie Curie (Paris 6), Paris, France.

Research grants

- Project Khun Phoom Foundation for Genomic study in autistic child Thailand
- Thailand Research Fund and Office of the Higher Education Commission.
- Thailand Project for Pharmacogenomics, Thailand Center of Excellence for Life Sciences (Thailand)/Mahidol University
- The Mahidol University (MU)/The Thailand Research fund and Office of the Higher Education Commission (New Researcher grant MRG5480136).
- Ramathibodi Cancer Research Project
- GlaxoSmithKline (GSK)

Career

- Lecturer at the Department of Pathobiology, Faculty of Science, Rangsit University, Thailand
- Project manager, Pharmacogenomics of Thailand, Thailand Center of Excellence for Life Sciences (TCELS), Ministry of Sciences
- Project coordinator "National cord blood bank and stem cell therapy", "Biobank project", "Graduate study and Postdoctoral fellowships", "Emerging Infection Disease Research Institute and Bio-safety laboratories level 3- 4", "Dengue vaccine pilot plant", "Mini MBA in life sciences", Thailand Center of Excellence for Life Sciences (TCELS), Ministry of Sciences

Speaker

- Cytochrome P450: Biotransformation of xenobiotics, AFRIMS, Thailand
- HIV-1 drug resistance, Medical technologist association and National Health Scheme,

Thailand

- Biosafety and Biosecurity:What you need to know when you working with the Isolation wards, Suratthani Hospital, Thailand
- Biosafety and Biosecurity: What you need to know when you working in Biomedical laboratory, Department of Pathology, Ramathibodi Hospital, Thailand, 2008
- Biological safety, Academic annual meeting, Royal College of Pathologist of Thailand, 2008
- The SNP genotyping facility using pyrosequencing, Genome Wide Association Analysis 2008, Center of Pharmacogenomics and Bioinformatics, Thailand

Research

Principle Investigator

- Monitoring and evaluation of transmitted antiretroviral drug resistance in treatment-naïve HIV-1 infected patients by genotypic resistance testing (EC approved)
- The study of disease progression markers (CD4, Viral load, CCR5, CXCR4, Anti-R7V antibody) in Thai Human Immunodeficiency Virus Type 1 Infection: A correlation of delayed disease progression to AIDS (EC approved)
- Epidemiological and Virological Study of Hand-Foot-and -Mouth Viruses in Children for Control, Prevention and Development of Laboratory Molecular diagnostic techniques (Submit)
- Molecular epidemiological study of prevalence and genotype in viruses related-Hand-Foot-Mouth disease to develop the clinical diagnostics tool by using molecular and Bioinformatics techniques
- Molecular epidemiological study of prevalence and HCV genotype in HCV-infected patients in Thailand
- Molecular Epidemiological Study to Monitor the Prevalence of Antiviral Drug Resistance in HBV Infected Patients by Genotypic Drug Resistance Testing
- Molecular epidemiological study to monitor the prevalence of antiretroviral drug resistance in HIV-1 infected patients by genotypic resistance testing

Team Investigator

- Study of gene expression profiling in HIV-1 infected patients after treatment with AZT, NVP, 3TC, EFV.

- Control and protection of hand foot and mouth diseases in children, and detection of virus; Real time-RT-PCR detection.
- Molecular epidemiological study of prevalence and HPV genotype in cervical cancer women
- Performance of PCR-Based Methods for Quantitative Determination of Viral Load in HIV-1 Infected Subjects
- Study for the Correlation between HIV-1 (CRF01_AE) Molecular Characteristics and Clinical Outcome to Achieve the Durable Efficacy of Antiretroviral Therapy

Publication

1. Yaowakulpatana K, Vadcharavivad S, Ingsathit A, Areepium N, Kantachuvesiri S, Phakdeekitcharoen B, **Sukasem C**, Sra-Ium S, Sumethkul V, Kitiyakara C. [Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation.](#) Eur J Clin Pharmacol. 2015 Dec 4. [Epub ahead of print]
2. Damronglerd P, **Sukasem C**, Thipmontree W, **Puangpetch A**, Kiertiburanakul S. [A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study.](#) Pharmgenomics Pers Med. 2015 Oct 3;8:155-162. eCollection 2015.
3. Bushyakanist A, Puangpetch A, **Sukasem C**, Kiertiburanakul S. [The use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in Thailand.](#) Pharmgenomics Pers Med. 2015 Nov 5;8:163-170. eCollection 2015.
4. Suwalak T, Srisawasdi P, Puangpetch A, Santon S, Koomdee N, Chamnanphon M, Charoenyingwattana A, Chantratita W, **Sukasem C**. [Polymorphisms of the ApoE \(Apolipoprotein E\) Gene and Their Influence on Dyslipidemia in HIV-1-Infected Individuals.](#) Jpn J Infect Dis. 2015 Jan 26;68(1):5-12. doi: 10.7883/yoken.JJID.2013.190.
5. Hongkaew Y, Ngamsamut N, Puangpetch A, Vanwong N, Srisawasdi P, Chamnanphon M, Chamkrachchangpada B, Tan-kam T, Limsila P, **Sukasem C**. [Serum Prolactin level in Thai Children and Adolescents with Autistic Spectrum Disorder on Long Term Risperidone Treatments.](#) Thai J Pharmacol. 2015; 36(1): 26-35.

6. Vanwong N, Medhasi S, Pongchaidecha M, Ngamsamut N, Puangpetch A, Chamnanphon M, Chamkrachchangpada B, Tan-kam T, Hongkaew Y, Limsila P, **Sukasem C.**[Pharmacogenetics and Clinical Risk Factors for Risperidone-Related Weight Gain in Thai Autistic Spectrum Disorder Patients.](#) Thai J Pharmacol. 2015; 36(1): 13-25.
7. Trakulsrichai S, Sathirakul K, Auparakkitanon S, Krongvorakul J, Sueajai J, Noumjad N, **Sukasem C**, Wananukul W.[Pharmacokinetics of mitragynine in man.](#)Drug Des Devel Ther. 2015 Apr 29;9:2421-9. doi: 10.2147/DDDT.S79658. eCollection 2015.
8. Puangpetch A, Koomdee N, Chamnanphol M, Jantararoungtong T, Santon S, Prommas S, Hongkaew Y, **Sukasem C.**[HLA-B allele and haplotype diversity among Thai patients identified by PCR-SSOP: evidence for high risk of drug-induced hypersensitivity.](#)Front Genet. 2015 Jan 22;5:478. doi: 10.3389/fgene.2014.00478. eCollection 2014.
9. Hongkaew Y, Ngamsamut N, Puangpetch A, Vanwong N, Srisawasdi P, Chamnanphon M, Chamkrachchangpada B, Tan-Kam T, Limsila P, **Sukasem C.**[Hyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidone.](#)Neuropsychiatr Dis Treat. 2015 Jan 22;11:191-6. doi: 10.2147/NDT.S76276. eCollection 2015.
10. **Sukasem C**, Atasilp C, Chansriwong P, Chamnanphon M, Puangpetch A, Sirachainan E.[Development of Pyrosequencing Method for Detection of UGT1A1 Polymorphisms in Thai Colorectal Cancers.](#)J Clin Lab Anal. 2014 Dec 26. doi: 10.1002/jcla.21820. [Epub ahead of print]
11. Suwalak T, Srisawasdi P, Puangpetch A, Santon S, Koomdee N, Chamnanphon M, Charoenyingwattana A, Chantratita W, **Sukasem C.**[The distribution of Apolipoprotein E gene polymorphism and their influences in dyslipidemias in HIV-1 infections.](#)Jpn J Infect Dis. 2014 Nov 25. [Epub ahead of print]
12. Manosuthi W, **Sukasem C**, Thongyen S, Nilkamhang S, Sungkanuparph S.[ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen.](#)J Antimicrob Chemother. 2014 Aug;69(8):2195-201. doi: 10.1093/jac/dku129.
13. **Sukasem C**, Chamnanphon M, Koomdee N, Santon S, Jantararoungtong T, Prommas S, Puangpetch A, Manosuthi W.[Pharmacogenetics and Clinical Biomarkers for Subtherapeutic](#)

- [Plasma Efavirenz Concentration in HIV-1 Infected Thai Adults](#). Drug Metab Pharmacokinet. 2014 Aug 25;29(4):289-95.
14. **Sukasem C**, Puangpetch A, Medhasi S, Tassaneeyakul W. [Pharmacogenomics of drug-induced hypersensitivity reactions: challenges, opportunities and clinical implementation](#). Asian Pac J Allergy Immunol. 2014 Jun;32(2):111-23.
 15. **Sukasem C**, Manosuthi W, Koomdee N, Santon S, Jantararoungtong T, Prommas S, Chamnanphol M, Puangpetch A, Sungkanuparph S. [Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism](#). Infection. 2014 Jun;42(3):469-74. doi: 10.1007/s15010-013-0560-6.
 16. Manosuthi W, **Sukasem C**, Thongyen S, Nilkamhang S, Sungkanuparph S. [ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen](#). J Antimicrob Chemother. 2014 Aug;69(8):2195-201. doi: 10.1093/jac/dku129. Epub 2014 Apr 30.
 17. Manosuthi W, **Sukasem C**, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S. [CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy](#). Int J Antimicrob Agents. 2014 Mar;43(3):292-6. doi: 10.1016/j.ijantimicag.2013.10.022.
 18. Manosuthi W, **Sukasem C**, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S. [CYP2B6 18492T>C polymorphism compromises efavirenz concentration in co-infected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1](#). Antimicrob Agents Chemother. 2014 Apr;58(4):2268-73. doi: 10.1128/AAC.02384-13. Epub 2014 Feb 3.
 19. **Sukasem C**, Chamnanphon M, Koomdee N, Santon S, Jantararoungtong T, Prommas S, Puangpetch A, Manosuthi W. [Pharmacogenetics and clinical biomarkers for subtherapeutic plasma efavirenz concentration in HIV-1 infected Thai adults](#). Drug Metab Pharmacokinet. 2014 Jan 28. [Epub ahead of print]
 20. Manosuthi W, **Sukasem C**, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S. [CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy](#). Int J Antimicrob Agents. 2014 Mar;43(3):292-6. doi: 10.1016/j.ijantimicag.2013.10.022.

21. Manosuthi W, **Sukasem C**, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S. [CYP2B6 18492T>C polymorphism compromises efavirenz concentration in co-infected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1](#). *Antimicrob Agents Chemother*. 2014 Feb 3. [Epub ahead of print]
22. **Sukasem C**, Chamnanphon M, Koomdee N, Santon S, Jantararoungtong T, Prommas S, **Puangpetch A**, Manosuthi W. [Pharmacogenetics and clinical biomarkers for subtherapeutic plasma efavirenz concentration in HIV-1 infected Thai adults](#). *Drug Metab Pharmacokinet*. 2014 Jan 28. [Epub ahead of print]
23. **Sukasem C**, Manosuthi W, Koomdee N, Santon S, Jantararoungtong T, Prommas S, Chamnanphol M, Puangpetch A, Sungkanuparph S. [Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism](#). *Infection*. 2013 Nov 30. [Epub ahead of print]
24. Wongkittichote P, **Sukasem C**, Kikuchi A, Aekplakorn W, Jensen LT, Kure S, Wattanasirichaigoon D. [Screening of SLC25A13 mutation in the Thai population](#). *World J Gastroenterol*. 2013 Nov 21;19(43):7735-42. doi: 10.3748/wjg.v19.i43.7735.
25. **Sukasem C**, Tunthong R, Chamnanphon M, Santon S, Jantararoungtong T, Koomdee N, Prommas S, Puangpetch A, Vathesatogkit P. [CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors](#). *Pharmgenomics Pers Med*. 2013 Aug 22;6:85-91. doi: 10.2147/PGPM.S42332.
26. Sensorn I, Sirachainan E, Chamnanphon M, **Pasomsub E**, Trachu N, Supavilai P, **Sukasem C**, Pinthong D. [Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen](#). *Pharmgenomics Pers Med*. 2013 Aug 26;6:93-8. doi: 10.2147/PGPM.S44006
27. Tunthong R, Vathesatogkit P, **Sukasem C**, **Puangpetch A**, **Chantratita W**, Angchaisuksiri P, Sura T, Pathumarak A, Yamwong S, Boonbaichaiyapruk S, Sritara P. Pharmacogenetic study of CYP 2C19 and clopidogrel dose adjustment according to platelet reactivity monitoring in atherothrombotic-risk patients in Thailand. *Curr Pharmacogenomics Person Med*. 2013; 11: 154-161.
28. **Srisawasdi P**, Suwalak T, **Sukasem C**, **Chittamma A**, Pocathikorn A, **Vanavanan S**, Puangpetch A, Santon S, Chantratita W, Kiertiburanakul S, Kroll MH. [Small-Dense LDL Cholesterol/Large-Buoyant LDL Cholesterol Ratio as an Excellent Marker for Indicating](#)

- [Lipodystrophy in HIV-Infected Patients](#). Am J Clin Pathol. 2013 Oct;140(4):506-15. doi: 10.1309/AJCPE5I3KELTBXEJ.
29. **Sukasem C**, Gatrungei M, Promso S, Cunningham P, Koomdee N, Chamnanphon M, Chantratita W. Pharmacogenetic testing for Abacavir Hypersensitivity screening in resource limited setting. Curr Pharmacogenomics Person Med. 2013 (Accepted and In press).
30. Sensorn I, Jantararoungtong T, Sirachainan E, Chamnanphol M, Trachu N, **Pasomsub E**, Supavilai P, Pinthong D, **Sukasem C**. Association of CYP3A, ABCB1 and ABCC2 Polymorphisms and Clinical outcomes of Thai Breast cancer Patients treated with Tamoxifen. Pharmgenomics Pers Med. 2013. (Accepted and In press).
31. **Sukasem C**, Tunthong R, Chamnanphon M, Santon S, Jantararoungtong T, Koomdee N, Prommas S, Puangpetch A, Vathesatogkit P. [CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors](#). Pharmgenomics Pers Med. 2013 Aug 22;6:85-91. doi: 10.2147/PGPM.S42332
32. Suwannarat P, Chamnanphon M, Ngamsamut N, Sinrachatanant A, Chamkrachchangpada B, Tan-kam T, **Puangpetch A**, **Sukasem C**, Limsila P. Molecular genetic analysis of CYP2D6 and HLA-B*15:02 in Thai autistic spectrum disorder children: Implication for pharmacogenetics testing and optimization of drug treatments. Thai J. Genet. 2013, 6(1) : 81-85.
33. **Sukasem C**, Sungkanuparph S. [Would a CYP2B6 test help HIV patients being treated with efavirenz?](#) Pharmacogenomics. 2013 Jul;14(9):999-1001. doi: 10.2217/pgs.13.69. No abstract available.
34. Chamnanphon M, Pechatanan K, Sirachainan E, Trachu N, **Chantratita W**, **Pasomsub E**, Noonpakdee W, Sensorn I, **Sukasem C**. [Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen](#). Pharmgenomics Pers Med. 2013 May 24;6:37-48. doi: 10.2147/PGPM.S42330. Print 2013.
35. Tan-Kam T, Suthisisang C, Pavasuthipaisit C, Limsila P, Puangpetch A, **Sukasem C**. [Importance of pharmacogenetics in the treatment of children with attention deficit hyperactive disorder: a case report](#). Pharmgenomics Pers Med. 2013;6:3-7. doi: 10.2147/PGPM.S36782. Epub 2013 Jan 11

36. **Sukasem C**, Chamnanphon M, Koomdee N, Puangpetch A, Santon S, Jantararoungtong T, Prommas S, **Chantratita W**, Manosuthi W. [High Plasma Efavirenz Concentration and CYP2B6 Polymorphisms in Thai HIV-1 Infections](#). Drug Metab Pharmacokinet. 2013 Oct 25;28(5):391-7.
37. Suwalak T, Srisawasdil P, Puangpetch A, Santon S, Koomdee N, Jantararoungtong T, Prommas S, Chamnanphon M, Chantratita W, **Sukasem C***. The distribution of apolipoprotein E gene polymorphism and their influences in dyslipidemias in HIV-1 infections. AIDS Research and Therapy. 2013. (submitted)
38. Wongkittichote P, **Sukasem C**, Kikuchi A, Aekplakorn W, Jensen LT, Kure S, Wattanasirichaigoon D. Genetic Screening of SLC25A13 Mutations in The Thai Population. Hum Mutat. 2013. (submitted)
39. Manosuthi W, **Sukasem C**, Mankatitham W, Lueangniyomkul A, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S. CYP2B6 Haplotype and Biological Factors Responsible for Hepatotoxicity in HIV-infected Patients Receiving Efavirenz-based Antiretroviral Therapy. Antimicrob Agents Chemother. 2013. (submitted)
40. Manosuthi W, **Sukasem C**, Mankatitham W, Lueangniyomkul A, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S. CYP2B6 18492T>C Polymorphism Compromises Efavirenz-based Antiretroviral Regimen in Co-infected HIV and Tuberculosis Patients Carrying CYP2B6 Haplotype *1/*1. AIDS Research and Therapy. 2013. (submitted)
41. **Sukasem C***, Manosuthi W, Koomdee N, Santon S, Jantararoungtong T, Prommas S, Chamnanphol M, Puangpetch A. Association of g.18492C>T polymorphisms of CYP2B6 and borderline subtherapeutic efavirenz level among Thai HIV-1 infections. Pharmacogenomics 2013. (submitted)
42. **Sukasem C** and Sungkanuparph S. Would a CYP2B6 test help HIV patients being treated with Efavirenz?, Pharmacogenomics. 2013. (Invitation to write an Editorial article and In press)
43. **Sukasem C***, Tunthong R, Pongpetch A, Pairoj V, Srichunrasami C, Santon S, Vathesatogkit P, Chantratita W. Genetic determinants of platelet response to clopidogrel in patients with atherothrombotic risks in Thailand. Pharmgenomics Pers Med. 2013 (Accepted and In press).

44. Sensorn I, Jantararoungtong T, Sirachainan E, Chamnanphol M, Trachu N, Pasomsub E, Supavilai P, Pinthong D, **Sukasem C***. Association of CYP3A, ABCB1 and ABCC2 Polymorphisms and Clinical outcomes of Thai Breast cancer Patients treated with Tamoxifen. *Pharmgenomics Pers Med*. 2013. (Accepted and In press).
45. Chamnanphon M, Sensorn I, Sirachainan E, Trachu N, Chantratita W, Pasomsub E, Noonpakdee W, **Sukasem C***. Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen. *Pharmgenomics Pers Med*. 2013. (Accepted and In press).
46. **Sukasem C***, Gatrungei M, Promso S, Cunningham P, Koomdee N, Chamnanphon M, Chantratita W. Pharmacogenetic testing for Abacavir Hypersensitivity screening in resource limited setting. *Curr Pharmacogenomics Person Med*. 2013 (Accepted and In press).
47. Srisawasdi P, Suwalak T, **Sukasem C***, Chittamma A, Pocathikorn A, Vanavanan S, Puangpetch A, Santon S, Chantratita W, Kiertiburanakul S, Kroll MH. Small-Dense LDL Cholesterol/Large-Buoyant LDL Cholesterol Ratio as an Excellent Marker for Indicating Lipodystrophy in HIV-Infected Patient. *Am J Clin Pathol*. 2013. (Accepted and In press)
48. Tunthong R, Vathesatogkit P, **Sukasem C***, Puangpetch A, Chantratita W, Angchaisuksiri P, Sura T, Pathumarak A, Yamwong S, Boonbaichaiyapruck S, Sritara P. Pharmacogenetic study of CYP 2C19 and clopidogrel dose adjustment according to platelet reactivity monitoring in atherothrombotic-risk patients in Thailand. *Curr Pharmacogenomics Person Med*. 2013. (Accepted and In press)
49. **Sukasem C***, Chamnanphol M, Koomdee N, Puangpetch A, Santon S, Jantararoungtong T, Prommas S, Manosuthi W. High Plasma Efavirenz Concentration and CYP2B6 Polymorphisms in Thai HIV-1 Infections. *Drug Metab Pharmacokinet*. 2013. Feb 12. [Epub ahead of print]
50. Manosuthi W, **Sukasem C**, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S. Impact of Pharmacogenetic Markers of CYP2B6, Clinical Factors, and Drug-Drug Interaction on Efavirenz Levels in HIV/Tuberculosis Co-Infected Patients. *Antimicrob Agents Chemother*. 2013 Feb;57(2):1019-24.
51. Tan-kam T, Suthisisang C, Pawasuthipaisit C, Limsila P, **Sukasem C***. Use of Pharmacogenetics in the Treatment of Children with Attention Deficit Hyperactive Disorder in Thailand *Pharmgenomics Pers Med*. 2013;6:3-7.

52. Manosuthi W, **Sukasem C**, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S. [Impact of Pharmacogenetic Markers of CYP2B6, Clinical Factors, and Drug-Drug Interaction on Efavirenz Concentrations in HIV/Tuberculosis-Coinfected Patients](#). Antimicrob Agents Chemother. 2013 Feb;57(2):1019-24. doi: 10.1128/AAC.02023-12. Epub 2012 Dec 17
53. **Sukasem C**, Cressey TR, Prapaithong P, Tawon Y, Pasomsub E, Srichunrusami C, Jantararoungtong T, Lallement M, Chantratita W. [Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults](#). Br J Clin Pharmacol. 2012 Dec;74(6):1005-1012. doi: 10.1111/j.1365-2125.2012.04288.x.
54. **Sukasem C***, Prapaithong P., Pasomsub E., Srichunrusami C., Cressey TR., Jantararoungtong T., Chantratita W. Optimizing Efavirenz Treatment by Detection of Pharmacogenetic Markers of CYP2B6 Corrected with Plasma Concentration in HIV-1 Infections. Br J Clin Pharmacol. 2012 Dec;74(6):1005-12.
55. Sirachainan E, Jaruhathai S, Trachu N, Panvichian R, Sirisinha T, Ativitavas T, Ratanatharathorn V, **Sukasem C***. CYP2D6 polymorphisms influences the efficacy of adjuvant Tamoxifen in Thai breast cancer patients. Pharmgenomics Pers Med. 2012;5:149-53.
56. **Sukasem C***. Sirachainan E, Pechatanan K, Chamnanphon M., Sirisinha T, Ativitavas T, Panvichian R, Ratanatharathorn V, Sansorn I., Chantratita W, Impact of CYP2D6 polymorphisms on tamoxifen response of woman with breast cancer: A microarray-based study in Thailand. Asian Pac J Cancer Prev. 2012;13(9):4549-53.
57. Sirachainan E, Reungwetwattana T, Trachu N, Wisetpanit Y, Panvichian R, Sirisinha T, Ativitavas T, Ratanatharathorn V, **Sukasem C***. Pharmacogenetic study of 5-Fluorouracil-related severe toxicity in Thai cancer patients: a novel SNP detection. J Pharmacogenom Pharmacoproteomics. 2012; 3:112.
58. Manosuthi W, **Sukasem C**, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S. [Impact of Pharmacogenetic Markers of CYP2B6, Clinical Factors, and Drug-Drug Interaction on Efavirenz Concentrations in HIV/Tuberculosis Co-Infected Patients](#). Antimicrob Agents Chemother. 2012 Dec 17. [Epub ahead of print]

59. Manosuthi W, **Sukasem C**, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S. [Impact of pharmacogenetic markers of CYP2B6 and clinical factors on plasma efavirenz level in HIV/tuberculosis co-infected Thai patients.](#) J Int AIDS Soc. 2012 Nov 11;15(6):18410. doi: 10.7448/IAS.15.6.18410
60. Sirachainan E, Jaruhathai S, Trachu N, Panvichian R, Sirisinha T, Ativitavas T, Ratanatharathorn V, Chamnanphon M, **Sukasem C**. [CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients.](#) Pharmgenomics Pers Med. 2012;5:149-53. doi: 10.2147/PGPM.S32160. Epub 2012 Oct 17.
61. Punyacam P, Iemwimangsa N, Chantratita W, **Sukasem C**, Sungkanuparph S. [HIV drug resistance interpreted by cumulative versus last genotypes in HIV-infected patients with multiple treatment failures.](#) Curr HIV Res. 2012 Apr;10(3):271-4.
62. Sungkanuparph S, **Sukasem C**, Kiertiburanakul S, Pasomsu E, Chantratita W. [Emergence of HIV-1 drug resistance mutations among antiretroviral-naïve HIV-1-infected patients after rapid scaling up of antiretroviral therapy in Thailand.](#) J Int AIDS Soc. 2012 Mar 12;15(1):12.
63. Sungkanuparph S, Kiertiburanakul S, **Sukasem C**, Chantratita W. [Discrepancies Between WHO 2009 and IAS-USA 2009 Lists for Determining the Rate of Transmitted HIV-1 Drug Resistance: A Prospective Study.](#) J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):e3-5. No abstract available.
64. Chantratita W, **Sukasem C**, Sirinavin S, Sankuntaw N, Srichantaratsamee C, **Pasomsu E**, Malathum K. Simultaneous detection and subtyping of H274Y-positive influenza A (H1N1) using pyrosequencing. J Infect Dev Ctries. 2011 May 28;5(5):348-52.
65. Pongthanapitsith V, **Sukasem C**, Premchaiporn K, Srichantaratsamee C, **Chantratita W**. Clinical performance of three rapid diagnostic tests for influenza virus in nasopharyngeal specimens to detect novel swine-origin influenza viruses. Infection. 2011 Apr;39(2):105-11. Epub 2011 Mar 22
66. **Sukasem C**, Pairoj W, Saekang N, Pombubpha H, Srichunrasami C, Pongtippan A, Junyangdikul P, Chantratita W. Molecular epidemiology of human papillomavirus genotype in women with high-grade squamous intraepithelial lesion and cervical cancer: will a quadrivalent vaccine be necessary in Thailand? J Med Virol. 2011 Jan;83(1):119-26.

67. Manosuthi W, Butler DM, Chantratita W, **Sukasem C**, Richman DD, Smith DM. Patients Infected with HIV Type 1 Subtype CRF01_AE and Failing First-Line Nevirapine- and Efavirenz-Based Regimens Demonstrate Considerable Cross-Resistance to Etravirine. *AIDS Res Hum Retroviruses*. 2010 May 27. [Epub ahead of print] No abstract available.
68. Pasomsub E, **Sukasem C**, Sungkanuparph S, Kijisirikul B, Chantratita W. The application of artificial neural networks for phenotypic drug resistance prediction: evaluation and comparison with other interpretation systems. *Jpn J Infect Dis*. 2010 Mar;63(2):87-94
69. Kiertiburanakul S, Wiboonchutikul S, **Sukasem C**, Chantratita W, Sungkanuparph S. Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting. *J Clin Virol*. 2010 Apr;47(4):330-4. [Epub 2010 Feb 24]
70. Sungkanuparph S, **Sukasem C**, Manosuthi W, Wiboonchutikul S, Piyavong B, Chantratita W. Tipranavir resistance associated mutations in protease inhibitor-naïve patients with HIV-1 subtype A/E infection. *J Clin Virol*. 2008 Nov;43(3):284-6.
71. Chantratita W, **Sukasem C**, Kaewpongsri S, Srichunrusami C, Pairoj W, Thitithanyanont A, Chaichoune K, Ratanakron P, Songserm T, Damrongwatanapokin S, Landt O. Qualitative detection of avian influenza A (H5N1) viruses: A comparative evaluation of four real-time nucleic acid amplification methods. *Mol Cell Probes*. 2008 Oct-Dec;22(5-6):287-93.
72. **Sukasem C**, Churdboonchart V, Sukeepaisarncharoen W, Piroj W, Inwisai T, Tiensuwan M, Chantratita W. Genotypic resistance profiles in antiretroviral-naïve HIV-1 infections before and after initiation of first-line HAART: impact of polymorphism on resistance to therapy. *Int J Antimicrob Agents*. 2008 Mar;31(3):277-81.
73. **C. Sukasem**, V. Churdboonchart, S. Chasombat, S. Kohreanudom, C. Watitpun, E. Pasomsub, W. Piroj, M. Tiensuwan, W. Chantratita. Surveillance of genotypic resistance mutations in HIV-1 treated individuals after completion of the National Access to Antiretroviral Program in Thailand. *Infection*, 2007; 35: 81-88.
74. **C. Sukasem**, V. Churdboonchart, S. Chasombat, S. Kohreanudom, C. Watitpun, W. Piroj, M. Tiensuwan, W. Chantratita. Prevalence of antiretroviral drug resistance in treated HIV-1 infected patients: under the initiative of access to the NNRTI-based regimen in Thailand. *Journal of Chemotherapy*, 2007; 19: 528-533.

75. **C. Sukasem**, V. Churdboonchart, K. Sirisidhi, S. Riengrojpitak, S. Chasombat, C. Watitpun, W. Piroj, M. Tiensuwan and W. Chantratita. Genotypic resistance mutations in treatment-naïve and treatment-experienced patients under widespread use of antiretroviral drug in Thailand: Implication for further epidemiologic surveillance, *Japanese Journal of Infectious Diseases*, 2007; 60: 284-289.
76. **C. Sukasem**, V. Churdboonchart, W. Sukeepaisarncharoen, W. Piroj, T. Inwisai, M. Tiensuwan, W. Chantratita. Genotypic resistance profiles in antiretroviral-naïve HIV-1 infections before and after initiation of first-line HAART: Impact of polymorphism on therapy resistance, *International Journal of Antimicrobial Agent and Chemotherapy*, 2008; 31: 277-281.
77. W. Chantratita, **C. Sukasem**, S. Kaewpongsri, C. Srichunrusami, W. Pairoj, A. Thitithanyanont, K. Chaichoune, P. Ratanakron, T. Songserm, S. Damrongwatanapokin, O. Landt. Qualitative detection of avian influenza A (H5N1) viruses: a comparative evaluation of four real time nucleic acid amplification methods. *Molecular and Cellular probe*, 2008.
78. S Sungkanuparph, **C. Sukasem**, W Manosuthi, S Wiboonchutikul, B Piyavong and W Chantratita. Tipranavir resistance in protease inhibitor-naïve patients with HIV-1 subtype A/E infection. *Journal of Clinical Virology*, 2008; 43:284-6.

Textbook

1. Maximize the effectiveness of HIV-1 treatment by using molecular techniques, bioinformatics and Pharmacogenomics, edited by W. Chantratita (2007), ISBN 9789740456797, **C. Sukasem** and Wasun Chantratita. 8 years monitoring of HIV-1 drug resistance in Thailand: the application of molecular technique and bioinformatics, 86-114.
2. Use of bioinformatics for extensive genome analysis, edited by W. Chantratita, **C. Sukasem** and S. Mahasirimongkon. (2008), ISBN 9789743499975, **C. Sukasem**. Pharmacogenetic testing and its application for Public Health in Thailand, 384-410.
3. Influenza A virus 2nd edition, edited by P. Bhattarakosol and P. Auewarakul (2008), ISBN 9749495039, **C. Sukasem**. Biosafety Laboratory Level 3: the need for Avian influenza working, 335-354.
4. Influenza A virus 2nd edition, edited by P. Bhattarakosol and P. Auewarakul (2008), ISBN

- 9749495039, W. Chantratita, **C. Sukasem** and W. Pairoj. Molecular Diagnostics of Influenza H1N1, H3N2 and H5N1. 219-243.
5. Biosafety and Biosecurity for Medical and Animal Laboratories, edited by **C. Sukasem**, S. Lousirojanakul, S. Barasrak and W. Viriyaraj (2011), ISBN, **C.Sukasem**, S. Lousirojanakul, S and P. Auewarakul. Biosafety and Biosecurity for Medical and Animal Laboratories: Introduction and Overview. 1-16.
 6. Biosafety and Biosecurity for Medical and Animal Laboratories, edited by **C. Sukasem**, S. Lousirojanakul, S. Barasrak and W. Viriyaraj (2011), ISBN, **C. Sukasem**. Principle of Laboratory Biosafety. 33-56.
 7. Biosafety and Biosecurity for Medical and Animal Laboratories, edited by **C. Sukasem**, S. Lousirojanakul, S. Barasrak and W. Viriyaraj (2011), ISBN, **C. Sukasem** and Aoranong Rachatachenchai. Principle of Laboratory Biosecurity. 57-72.
 8. Biosafety and Biosecurity for Medical and Animal Laboratories, edited by **C. Sukasem**, S. Lousirojanakul, S. Barasrak and W. Viriyaraj (2011), ISBN, **C. Sukasem**, S. Blacksell and S. Barasrak. Laboratory for Medical Diagnostic and Research, 121-152.
 9. Clinical Pathology, edited by Mana Rochanawutanon (2013). ISBN, **C. Sukasem**, Molecular Diagnostic and Research Techniques.
 10. Clinical Pathology, edited by Mana Rochanawutanon (2013). ISBN, **C. Sukasem**, Pharmacogenomics and Personalized Medicine

International and National Presentation

- Oral presentation " The presence of anti-R7V antibodies in HIV-infected patients: a novel marker for the non-progression to AIDS", 8th International meeting on molecular epidemiology and evolutionary genetics in infectious diseases, Bangkok, Thailand; 2006.
- Oral presentation "Surveillance of genotypic resistance mutations in chronic HIV-1 treated individuals after completion of the National Access to Antiretroviral Program in Thailand", 2nd meeting on HIV drug resistance workshop: Basic principles and clinical implications, Bangkok, Thailand; 2007.
- Oral presentation 13th meeting on "AIDS and Flow cytometry, 2007" Thailand

Research of Interest

1. Pharmacogenomics and Pharmacogenetics

2. Functional genomics and Pharmacokinetics
3. Drug Metabolizing enzyme and Transporter gene in Thai population
4. Autistic child: Discovery of Diagnostic markers and Pharmacogenomics markers
5. Immunological repertoire: Immunoglobulin and T-cell repertoire by deep sequencer.